The balance of STING signaling orchestrates immunity in cancer
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 2×
“However, work by Ishikawa et al. 5 succeeding the discovery of STING concluded that IFNβ activation through STING involves the sensing of double-stranded DNA fragments independently of the already described DNA sensor, Toll-like receptor 9 (TLR9).”
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 3×
“In two seminal papers by Deng et al. 69 and Woo et al. 70 , it was demonstrated elegantly that tumor cell-derived DNA fragments elicit a type I IFN response by cGAS–STING that support dendritic cell antigen presentation capacity and activate cytotoxic tumor-specific CD8 + T cells.”
Molecular mechanisms and cellular functions of cGAS–STING signalling
Hopfner, K.-P., & Hornung, V. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0244-x · Cited by 2,052 · cited 1×
“Work by Cho et al. 60 found that nucleosome liberation of cGAS can be regulated through the double-strand break repair protein meiotic recombination 11 (MRE11).”
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Chromosomal instability drives metastasis through a cytosolic DNA response
Bakhoum, S. F., Ngo, B., Laughney, A. M., Cavallo, J.-A., Murphy, C. J., Ly, P., Shah, P., Sriram, R. K., Watkins, T. B. K., Taunk, N. K., et al. (2018) · Nature · doi:10.1038/nature25432 · Cited by 1,593 · cited 14×
“This can be detrimental for cancers and as a result a high degree of DDR regulation occurs in these cancers.”
InfluentialSTING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
DNA sensing by the cGAS–STING pathway in health and disease
Motwani, M., Pesiridis, S., & Fitzgerald, K. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0151-1 · Cited by 1,467
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · cited 1×
“94), which in mouse models recruit CD8 + T cells from the blood to the tumor 73 .”
Cytoplasmic chromatin triggers inflammation in senescence and cancer
Dou, Z., Ghosh, K., Vizioli, M. G., Zhu, J., Sen, P., Wangensteen, K. J., Simithy, J., Lan, Y., Lin, Y., Zhou, Z., et al. (2017) · Nature · doi:10.1038/nature24050 · Cited by 1,335
Fenech, M., Kirsch-Volders, M., Natarajan, A. T., Surralles, J., Crott, J. W., Parry, J., Norppa, H., Eastmond, D. A., Tucker, J. D., & Thomas, P. (2011) · Mutagenesis · doi:10.1093/mutage/geq052 · Cited by 1,244 · cited 1×
“Micro-nuclei are small membrane-bound intracellular vesicles containing DNA 48 .”
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence
Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196 · cited 1×
“This IFN-independent promotion of senescence-associated secretory phenotype paracrine senescence by STING activity in the TME drives inflammation and thus supports anti-tumoral control 109–111 .”
Targeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178 · cited 4×
“The use of H-151 across 42 human cancer cell lines expressing STING shows that IL-6 secretion following genotoxic stress (by topoisomerase 1 and 2 inhibition) can be partly resolved by the use of STING antagonists 41 .”
InfluentialStructural basis of STING binding with and phosphorylation by TBK1
Zhang, C., Shang, G., Gui, X., Zhang, X., Bai, X.-C., & Chen, Z. J. (2019) · Nature · doi:10.1038/s41586-019-1000-2 · Cited by 1,095
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902 · cited 1×
“For example, as mentioned previously, STING activation can lead to upregulation of the checkpoint molecule PD-L1 on cancer cells, and subsequently support immune evasion 149,150 .”
Catastrophic nuclear envelope collapse in cancer cell micronuclei
Hatch, E. M., Fischer, A. H., Deerinck, T. J., & Hetzer, M. W. (2013) · Cell · doi:10.1016/j.cell.2013.06.007 · Cited by 741 · cited 1×
“For some CIN hi cancers, however, the cGAS–STING pathway is activated through noncanonical NF-κB signaling that drives tumor metastasis, creating a beneficial mechanism for defects in DDR 49,50 (discussed at the end of this Review).”
An orally available non-nucleotide STING agonist with antitumor activity
Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., et al. (2020) · Science · doi:10.1126/science.aba6098 · Cited by 694 · cited 1×
“For example, MSA-2 was designed as an oral prodrug that transforms into a highly selective STING ligand in low pH conditions (a hallmark for many TMEs) 87 .”
Dunphy, G., Flannery, S. M., Almine, J. F., Connolly, D. J., Paulus, C., Jønsson, K. L., Jakobsen, M. R., Nevels, M. M., Bowie, A. G., & Unterholzner, L. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.034 · Cited by 648 · cited 3×
“These findings substantiate previous investigations from Dunphy et al. 40 who demonstrated that treatment with the chemotherapeutic etoposide induced an acute non-canonical STING pathway activation, leading to subsequent NK-κB-driven expression of IFNβ and IL-6, diverging from the more delayed…”
Gaidt, M. M., Ebert, T. S., Chauhan, D., Ramshorn, K., Pinci, F., Zuber, S., O’Duill, F., Schmid-Burgk, J. L., Hoss, F., Buhmann, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.039 · Cited by 638
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589 · cited 1×
“In the latter case, this can occur either through epigenetic suppression or by indirectly preventing STING activation 154,155 .”
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 6×
“Advancements in our understanding of cancer immunology have paved the way for immunotherapeutic interventions, exemplified by the remarkable clinical success of immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated p…”
InfluentialMagnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.047 · Cited by 451 · cited 3×
“Low-dose STING agonist treatment limits lymphocyte depletion in treated tumors and achieves control of distal tumors when combined with anti-PD-1 antibody (PD-1) 83 .”
Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1963 · Cited by 418 · cited 1×
“Unfortunately, many of those earlier developed compounds (such as ADU-S100, MK-1454 and BMS-986301) seem to have safety issues, poor pharmacokinetics, requirement of intratumoral administration and limited objective clinical responses 84–86 .”
SLC19A1 transports immunoreactive cyclic dinucleotides.
Luteijn, R. D., Zaver, S. A., Gowen, B. G., Wyman, S. K., Garelis, N. E., Onia, L., McWhirter, S. M., Katibah, G. E., Corn, J. E., Woodward, J. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1553-0 · Cited by 379
Wu, J., Dobbs, N., Yang, K., & Yan, N. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.009 · Cited by 373 · cited 3×
“Inde-pendently, these three groups developed a mouse model consisting of a single amino acid substitution Ser365Ala in the C-terminal tail of STING 19,39,116 .”
Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death
Larkin, B., Ilyukha, V., Sorokin, M., Buzdin, A., Vannier, E., & Poltorak, A. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601999 · Cited by 361
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348
SLC19A1 is an importer of the immunotransmitter cGAMP.
Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C., & Li, L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.006 · Cited by 333
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Li, J., Duran, M. A., Dhanota, N., Chatila, W. K., Bettigole, S. E., Kwon, J., Sriram, R. K., Humphries, M. P., Salto-Tellez, M., James, J. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0387 · Cited by 312 · cited 1×
“The role of ENPP1 has garnered increasing attention in the cancer field, as its degradation of 2′3′-cGAMP supports the production of immunosuppressive adenosine molecules as drivers of immune evasion and cancer metastasis 133,134 .”
Tight nuclear tethering of cGAS is essential for preventing autoreactivity
Volkman, H. E., Cambier, S., Gray, E. E., & Stetson, D. B. (2019) · eLife · doi:10.7554/elife.47491 · Cited by 303
The molecular basis of tight nuclear tethering and inactivation of cGAS
Zhao, B., Xu, P., Rowlett, C. M., Jing, T., Shinde, O., Lei, Y., West, A. P., Liu, W. R., & Li, P. (2020) · Nature · doi:10.1038/s41586-020-2749-z · Cited by 261
Loo, T. M., Miyata, K., Tanaka, Y., & Takahashi, A. (2020) · Cancer Science · doi:10.1111/cas.14266 · Cited by 232 · cited 1×
“Cellular senescence is known for its tumor suppression mechanism and can be linked directly to a senescence-associated secretory phenotype 108 .”
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
Ghosh, M., Saha, S., Li, J., Montrose, D. C., & Martinez, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.023 · Cited by 166 · cited 1×
“The degradation of TREX1 mediated by p53, thus increases cytosolic DNA accumulation and STING activation 45 .”
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107
Epigenetic state determines the in vivo efficacy of STING agonist therapy
Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94 · cited 1×
“Indeed, by depleting DNA methyltransferase 3α and 3β (DNMT3A and DNMT3B), STING levels have been observed to increase 156 .”
Benoit-Lizon, I., Jacquin, E., Rivera Vargas, T., Richard, C., Roussey, A., Dal Zuffo, L., Martin, T., Melis, A., Vinokurova, D., Shahoei, S. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003459 · Cited by 85
Ni, H., Zhang, H., Li, L., Huang, H., Guo, H., Zhang, L., Li, C., Xu, J.-X., Nie, C.-P., Li, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005151 · Cited by 85
Metadata
- Authors
- Lanng, K. R. B., Lauridsen, E. L., & Jakobsen, M. R.
- Venue
- Nature Immunology
- Published
- 2024-06-25
- Volume
- 25
- Issue
- 7
- Pages
- 1144-1157
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W4400007738
- Cited by
- 161
- References
- 40
- FWCI
- 22.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.